RxDoctor Payments Data

Jaya Kumar, MD

Ophthalmology · Orlando, FLNPI 1871855049

Payments from drug & device makers

$19,750in general payments, 2019–2025

Across 216 payments — averaging $91.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Novartis$4K
  • US Retina LLC$2K
  • Alimera Sciences, Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Genentech USA, Inc.$1K
  • plus $2K from 12 others
$4,955in research payments, 2019–2025

Across 8 payments — averaging $619.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$5K

What the payments were for

  • Consulting fees$9,93351%
  • Speaking & faculty fees$1,2006%
  • Travel & lodging$640%
  • Food & beverage$6,01231%
  • Ownership interest$7584%
  • Other$1,6638%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,750 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$5,081,656
Medicare patients
1,543
Services billed
39,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept49$140,807
SyfovrePegcetacoplan/Pf34$105,120
VabysmoFaricimab-Svoa20$66,226
Prednisolone Acetate255$6,956
LumiganBimatoprost12$3,967
Bromfenac Sodium24$3,569
CombiganBrimonidine Tartrate/Timolol16$3,094
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha175$2,219
Ketorolac Tromethamine69$1,941
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat110$1,403
Latanoprost131$1,368
Atropine Sulfate51$1,283
Brimonidine Tartrate106$1,115
Timolol Maleate82$655
Dorzolamide Hcl12$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Regeneron Healthcare Solutions, Inc.Eylea$1,270$140,80749 claims
Apellis Pharmaceuticals, Inc.Syfovre$462$105,12034 claims
Genentech USA, Inc.Vabysmo$1,004$66,22620 claims
AbbVieLumigan, Combigan$6,986$7,06028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →